Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pivotal trial of HOLOGENE 5 in inherited epidermolysis bullosa
2018-000261-36Phase 2Active
- Sponsor
- Holostem
- Start
- Apr 2020
- Modality
- Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Hologene 5 in epidermolysis bullosa (EB), sponsored by Holostem. Primary endpoint: Primary: transplantation success at 12 months. Started Apr 2020; status: active.
02
Drugs
Hologene 5
03
Conditions
epidermolysis bullosa (EB)
Beyond the preview
Go deeper on 2018-000261-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000261-36.